Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
73.62
-0.72 (-0.97%)
Streaming Delayed Price
Updated: 12:45 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Gilead Sciences
< Previous
1
2
3
4
5
6
7
8
9
...
33
34
Next >
Large Cap Biopharmaceuticals Performance
May 20, 2024
The biotech sector remains a laggard YTD as can be seen by the IBB.
Via
Talk Markets
Gilead's Recently Acquired Liver Disease Candidate Shows Improvements In Disease Progression And Associated Itch
May 20, 2024
Gilead Sciences reports interim results from the ASSURE study of seladelpar in primary biliary cholangitis, showing significant improvements in cholestasis markers and pruritus.
Via
Benzinga
Penny Stock Sleepers: 7 Under-the-Radar Gems Ready to Launch
May 16, 2024
Penny stocks to buy understandably offers many enticing attributes, not least of which is the potential for tremendous returns.
Via
InvestorPlace
Market Whales and Their Recent Bets on GILD Options
May 15, 2024
Via
Benzinga
Decoding Gilead Sciences's Options Activity: What's the Big Picture?
May 10, 2024
Via
Benzinga
Why NASDAQ:GILD qualifies as a good dividend investing stock.
May 09, 2024
Why GILEAD SCIENCES INC (NASDAQ:GILD) is a Top Pick for Dividend Investors.
Via
Chartmill
$1000 Invested In This Stock 20 Years Ago Would Be Worth $9,300 Today
May 07, 2024
Via
Benzinga
Gilead Sciences Unusual Options Activity For May 06
May 06, 2024
Via
Benzinga
How Is The Market Feeling About Gilead Sciences?
May 06, 2024
Via
Benzinga
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
May 09, 2024
These biotech breakthrough stocks give investors a glimpse into medicine's future -- and massive moneymaking opportunities to boot.
Via
InvestorPlace
Bargain Hunting: 7 Stocks Near 52-Week Lows to Buy Before the Bounce Back
May 06, 2024
If you want your shot at significant upside, speculate on these stocks near 52-week lows that can prove the critics wrong.
Via
InvestorPlace
Shhh! 3 Secret Biotech Stocks Flying Below Wall Street’s Radar
May 01, 2024
These biotech stocks seem to be rich with intriguing growth plays going for very reasonable multiples this May.
Via
InvestorPlace
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
April 29, 2024
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Gilead Sciences Unusual Options Activity
April 26, 2024
Via
Benzinga
3 Dividend Stocks to Buy at a 52-Week Low in April
April 26, 2024
Explore these three dividend stocks trading near their 52-week lows, presenting compelling opportunities for income-oriented investors.
Via
InvestorPlace
Will Gilead's Big Veklury Beat Offset A Cancer Drug Miss?
April 25, 2024
Gilead beat first-quarter calls, but it came on the back of Covid drug Veklury.
Via
Investor's Business Daily
Exposures
COVID-19
The Analyst Verdict: Gilead Sciences In The Eyes Of 12 Experts
April 19, 2024
Via
Benzinga
What the Options Market Tells Us About Gilead Sciences
April 18, 2024
Via
Benzinga
Gilead Sciences (GILD) Q1 2024 Earnings Call Transcript
April 25, 2024
GILD earnings call for the period ending March 31, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
GILD Stock Earnings: Gilead Sciences Beats EPS, Beats Revenue for Q1 2024
April 25, 2024
GILD stock results show that Gilead Sciences beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Stocks Drop, Tech Tumbles With Meta's Weak Outlook, Q1 Stagflation Fears; Gold Miners Advance: What's Driving Markets Thursday?
April 25, 2024
Wall Street suffers a double blow in Thursday’s session, as softer-than-expected revenue forecasts from Meta Platforms Inc. (NASDAQ:META) are being compounded by weaker-than-expected economic growth...
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
If You Invested $100 In This Stock 20 Years Ago, You Would Have $900 Today
April 17, 2024
Via
Benzinga
Why the dividend investor may take a look at NASDAQ:GILD.
April 17, 2024
Uncovering Dividend Opportunities with GILEAD SCIENCES INC (NASDAQ:GILD).
Via
Chartmill
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields
April 25, 2024
Via
Benzinga
US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst
April 25, 2024
The back-and-forth motion in the market continues, with the index futures pointing to a lower opening on Thursday. Meta Platforms, Inc.’s (NASDAQ:META)
Via
Benzinga
Why Is Penny Stock HOOKIPA Pharma Trading Higher On Wednesday?
April 24, 2024
HOOKIPA Pharma secures FDA clearance for its innovative HB-700 therapeutic vaccine targeting KRAS-mutated cancers. Learn about its broad impact on lung, colorectal, and pancreatic cancers, achieving...
Via
Benzinga
Exposures
Product Safety
Undervalued Icons: 3 Household Names Trading at Steep Discounts
April 22, 2024
Three of Wall Street's undervalued stocks could provide a unique blend of stability and long-term growth potential.
Via
InvestorPlace
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
April 19, 2024
Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—the highest safety-rel
Via
Benzinga
Exposures
Product Safety
Better Growth Play: Merck or The Vanguard Growth Index Fund?
April 15, 2024
Merck's shares are trading in bargain territory. Are they a better growth play than this popular Vanguard fund?
Via
The Motley Fool
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
April 21, 2024
Corporate profit growth rose in Q3 2023 and is expected to continue in Q1.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
33
34
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.